More Hematology Letters Link

As AI revolutionizes cancer care by enhancing diagnosis, treatment, and clinical trial matching, it may lead to improved patient outcomes and streamlined workflows.

Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.

The frequency and severity of adverse effects for the combination were consistent with expected safety findings for each individual agent.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Busulfan/melphalan elicited higher PFS among patients with ISS2 or ISS3 disease, and melphalan-200 improved PFS in ISS1 disease.